Drug intelligence / Profile preview

CLL1 CAR-NK cell

Development stage: Phase 1
Lead developer: Qihan Biotech
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Injection

Overview

CLL1 CAR-NK cell is an investigational Chimeric Antigen Receptor (CAR) Natural Killer (NK) cell therapy designed to target both CD33 and CLL1 antigens. It is being evaluated in an open-label, nonrandomized, investigator-initiated clinical trial for patients with acute myeloid leukemia (AML). The study aims to assess its safety, tolerability, pharmacokinetics, and efficacy, as well as to determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D). The treatment involves multiple administrations of CAR-NK cells, with initial doses of 2.0×10^9 cells followed by 3.0×10^9 cells in subsequent administrations.

Other names: dual CD33-CLL1 CAR-NK cells

Targets

CLEC12ACD33 (Myeloid cell surface antigen CD33)

Beyond the preview

Go deeper on CLL1 CAR-NK cell.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CLL1 CAR-NK cell.

Explore the full profile